• Rheumatic patients are at risk of developing infections because their immunocompromised state. • Biologics or small-molecules would not appear to be related to increased or reduced susceptibility of COVID-19. • DMARDS (traditional and biologics) and small molecules can be probably used at different timings of the disease. • The use of immunosuppressant for prophylaxis of COVID-19 is still a matter of debate. • Patient surveillance and the endorsement of extensive preventive barrier measures is mandatory.